This ASX healthcare share just crashed 49%, here’s why

A young businesswoman looks shocked at what she's reading on the paperwork in her hand, with colleagues in the office in the background.A young businesswoman looks shocked at what she's reading on the paperwork in her hand, with colleagues in the office in the background.

In case you were wondering, it is the Kazia Therapeutics Ltd (ASX: KZA) share price that’s crashing heavily today.

After opening at 35 cents for the day, shares in the oncology-focused drug development company are continuing to freefall.

At the time of writing, Kazia shares are fetching a multi-year low of 26 cents, down 49.02%.

Let’s take a look at what could be causing this downfall.

What did Kazia update the ASX with?

Investors are heading for the exits following the company’s latest progress update on its GBM Agile pivotal study.

A brain-penetrant inhibitor, paxalisib is under development to treat glioblastoma which is a common and very aggressive brain cancer.

According to the release the Global Coalition for Adaptive Research (GCAR), the sponsor of the study, advised Kazia that the treatment arm did not meet pre-defined criteria for continuing to a second stage.

This comes despite the first stage of the paxalisib arm completing recruitment.

While no reason was given, the patients enrolled in the first stage will continue with their treatment as per protocol.

Kazia anticipates it will receive the final analysis of study results in the second half of the next calendar year.

Following the outcome, the study will not open to the paxalisib arm in Germany or China.

Although, Kazia stated it will work with its licensing partner to determine the way forward in China.

Management commentary

Kazia CEO Dr James Garner said:

GBM AGILE was designed as an adaptive study, with the potential to follow a range of different paths to completion.

Today’s news defines the remaining trajectory of the study, with modestly positive implications for both costs and timelines, and with some specific consequences for regulatory strategy in China. It does not allow us to draw any meaningful inferences about the outcomes of the study, and indeed it is critical for regulatory purposes that we remain blinded to the evolving data.

We look forward to reporting final results in 2H CY2023, as currently planned.

Garner went on to add:

In the meantime, we are excited by some of the emerging data in diffuse intrinsic pontine glioma (DIPG) and brain metastases, which have become increasingly important areas of focus for the company and look forward to sharing more detail on those activities in due course.

Kazia share price snapshot

While nobody likes their stock falling, it’s been a difficult 12 months for Kazia shareholders.

After reaching a 52-week high of $1.65 towards the back end of last year, it has been all downhill ever since.

Kazia shares have lost more than 75% of their value in 2022.

The post This ASX healthcare share just crashed 49%, here’s why appeared first on The Motley Fool Australia.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.* Scott just revealed what he believes could be the “five best ASX stocks” for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now

See The 5 Stocks
*Returns as of July 7 2022

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/g53cG2s

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s